NORCROSS, Ga., Dec. 15, 2005 (PRIMEZONE) -- Auriga Laboratories, Inc., a leading specialty pharmaceutical company, today announced that the board of directors has elected Philip S. Pesin to serve as chairman, effective immediately. Mr. Pesin succeeds Glynn Wilson, Ph.D., who serves as the company's President.
Mr. Pesin, who has been a member of Auriga's board since inception, brings extensive experience in establishing innovative companies in the pharmaceutical and other industries.
An attorney and certified public accountant, Mr. Pesin is the managing director of The Sorrento Financial Group, LLC, a financial services company specializing in private equity investment with a focus on financing innovative, high-growth companies.
Mr. Pesin is a licensed attorney in California and the District of Columbia, and holds a Master of Laws degree from The Georgetown University Law Center, a Juris Doctor from the University of San Diego School of Law, and a Bachelor of Science in Finance from The University of Arizona.
About Auriga
Auriga Laboratories, Inc., develops and markets new prescription products for approved drugs using proprietary drug delivery technologies and reformulation strategies. The specialty pharmaceutical company is based in Norcross, Georgia. A highly integrated team of experienced pharmaceutical industry executives manages product life cycle from development through marketing and sales. The company currently markets Extendryl(r), a prescription cough/cold medication, and Trycet(tm), used to manage pain. More information is available at the company's website at: http://www.aurigalabs.com.